According to a recent market study published by Growth Market Reports, titled, " Global Recombinant Human Serum Albumin Market by types, applications, end-users and regions: Size, Share, Trends and Opportunity Analysis, 2017-2027", the market was valued at USD 56.2 Million in 2019 and is anticipated to grow at a healthy growth rate of 8.6% by the year 2027. The global recombinant human serum albumin market is anticipated to grow significantly during forecast period.

Request a free sample copy @ https://growthmarketreports.com/request-sample/2516

Global recombinant human serum albumin market has been segmented based on by types, applications, end-users and regions. In terms of types, the global recombinant human serum albumin is categorized as OsrHSA and ScrHSA. On the basis of application, the market is segmented into cell culture media, stem cell therapy, vaccine production, drug formulations, medical device coating and others. Based on end-users, the market is categorized into pharmaceutical and biotechnology companies, hospitals and clinics, and research institutes. By regions the global recombinant human serum albumin market is segmented as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA).

Recombinant Human Serum Albumin also known as rHSA is plant-based medium derived from Oryza sativa (rice grain) or Saccharomyces Cerevisiae i.e., baker’s yeast. rHSA has better consistency and equivalent or even better performance than plasma-derived HSA in fostering cell growth. The usage of rHSA is amplifying in the global market. It is animal component-free, virus and prion-free, thus, limiting the risk of bacterial contamination as compared to plasma derived HSA.

The COVID-19 pandemic has had a serious impact on the society and overall economy of the world. The impact of COVID-19 is growing by the day and affecting the several markets. The coronavirus pandemic is creating uncertainty across markets and reducing business confidence. Gradually industries are recovering from severe impact of the pandemic. But, evidently the global recombinant human serum albumin market has been impacted positively in most business areas. The demand for recombinant human serum albumin is rapidly rising as an aftermath of COVID across all end use industries.

rHSA is plant-derived, thus eliminating the threat of viral and bacterial contaminations. Moreover, the high-quality consistency of rHSA reduces time and offers high-grade performance. rHSA supplements cell culture media to encourage cell growth and amplify recombinant protein yield. rHSA acts as an additive in serum-free or reduced serum culture media. It is used in the cryopreservation of cells. rHSA is apt for applications such as electrophoresis, where protein contaminants are undesirable. rHSA is used in ELISA applications and as a blocking agent in Western blots. rHSA is more homogeneous than plasma-derived HSA. It lacks immunogenicity & toxicity and offers a distinct and uniform medium. rHSA helps in long-term storage. It is used to enhance stem cell growth in liver, kidney, cardiac, keratinocyte, embryonic, mesenchymal, neural, and fibroblast stem cells. rHSA is used as an alternative to plasma-drive HSA in human therapeutics, cell culture media, diagnostic test kits, and research & development. The end-users of rHSA includes hospitals & clinics, pharmaceutical & biotechnological industry, and research institutes.

The development of a cost-effective technique for the production of recombinant HSA (rHSA) by employing yeast or rice seeds was adopted. The contamination caused by pHSA and bHSA were overcomed by using rHSA.

The requirement of high dosage of human serum albumin in clinical applications surge for the large-scale production of OsrHSA. The manufacturing of OsrHSA requires field production of transgenic rice. Field trail of transgenic plant raises concerns of environmental safety, since rice is a staple food worldwide. Of late, rice was listed as a advantageous host for molecular farming since, rice is a highly self-pollinated crop, and rice pollen is remarkably short-lived (<10 min) when it is out of the anther; regarding biosafety assessment of transgenic rice, it showed a very low frequency (0.04–0.80%) of pollen-mediated gene flow between genetically modified (GM) rice and adjacent non-GM plants. This low frequency can be decreased to negligible levels by a short spatial isolation.

Key Takeaways from the Study:

  • The market in North America holds a significant market share, 34.5% in 2019 and is anticipated to reach 36.5 Million by the end of 2027.
  • Growing demand from the pharmaceutical and biotechnology companies segment anticipated to drive the market growth during the forecast period.
  • Increasing demand from the end-users is projected to boost the market growth during the forecast period.
  • The cell culture media segment hold the market share, 39 % in 2019 and is anticipated to reach 39.5% by the end of 2027.
  • Increasing adoption of rHSA as a drug release carrier is estimated to positively influence the market growth during the forecast period.
  • The pharmaceutical and biotechnology companies segment holds a market share of 47.2% in 2019 and is anticipated to reach 48.6% by the end of 2027.

Report Scope:

Report Metric

Details

Market Value in 2019

USD 56.2 Million

Market Growth Rate (from 2020 to 2027)

8.6%

Historical Data

2017 & 2018

Base Year

2019

Forecast Period

2020 – 2027

Market Segments

Types, Applications, and End-users

Region Scope

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA)

Key Companies Profiled

Albumedix, Merck KGaA, InVitria, HiMedia Laboratories, Wuhan Healthgen Biotechnology Corp, Cyagen Biosciences, ScienCell Research Laboratories, Inc., Lee BioSolutions (Medix Biochemica), Lazuline, Akron Biotech, and Proteintech Group, Inc

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail tailor-made purchase options to meet your research requirements.

Target Audience:

  • Demand Side: pharmaceutical, hospitals and clinics, and research institutes.
  • Regulatory Side: Concerned government authorities, commercial research & development (R&D) institutions, and other regulatory bodies.
  • Associations and Industry Bodies: International Organization for Standardization, U.S. Food and Drug Administration, US Department of Agriculture (USDA) and European regulatory authorities.